Who we are
History
- Nov Took over the manufacturing and sales of Diazoxide in Japan from MSD K.K.
- Dec Merged Nagoya office into Tokyo office.
- Mar Started Rasilez sales.
- Jan Took over the manufacturing and sales of Rasilez in Japan from Novartis Pharma K.K.
- Apr Started Diazoxide sales according to sales rights acquisition of Diazoxide from MSD K.K.
- Mar Terminated co-promotion of Nopicor
- Oct Started Dantrium and Astomin sales according to manufacture and sales rights acquisition of Dantrium and Astomin from Astellas Pharma Inc.
- May Relocated the head office to Hamamatsucho Bldg. （Address: 1-1-1 Shibaura, Minato-ku, Tokyo, Japan）
- Apr Started Somazon sales according to manufacture and sales rights acquisition of Somazon from Astellas Pharma Inc.
- Apr Sendai Office established
- Mar Commenced co-promotion of Nopicor（manufactured and distributed by TORAY MEDICAL CO.,LTD.)
- Jan Sapporo Office established
- Dec Fukuoka Office established
- Jul Nagoya Office established
- Aug Launched Normosang into market
- Jun Transferred Normosang approval from CMIC to OrphanPacific
- Jan Launched Buphenyl into market
- Dec Osaka Office established
- Nov Transferred Buphenyl approval from CMIC to OrphanPacific
- May OrphanPacific established
Business Locations
Head Office
Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo, Japan 105-0023
TEL:03-6779-8151
FAX:03-6683-7851
Tokyo Office
Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo, Japan 105-0023
TEL:03-6779-8151
FAX:03-6683-7851
Sapporo Office
13F Sapporo Center Bldg., 6-2-2 Kitagojonishi, Chuo-ku, Sapporo, Hokkaido 060-0005
TEL:011-252-2005
FAX:011-252-2010
Sapporo Distribution center
Sendai Office
Sendai Mark One Bldg. 14F, 1-2-3 Chuo, Aoba-ku, Sendai, Miyagi
980-0811
TEL:022-217-7287
FAX:022-217-7289
Nagoya Distribution center
Osaka Office
Nakanoshima Central Tower 7F, 2-2-7, Nakanoshima, Kita-ku, Osaka
530-0005
TEL:06-6233-1730
FAX:06-6202-8155
Fukuoka Office
Fukuoka Asahi Kaikan 9F, 2-8-41 Tenjin, Chuo-ku, Fukuoka 810-0001
TEL:092-735-7150
FAX:092-735-7151
Structure of OrphanPacific
Organization of OrphanPacific
(As of June 1, 2021)
5 strengths of OrphanPacific
Business Model
We will achieve orphan drug creation with an innovative business model.
Our group covers the whole spectrum of pharmaceutical activities from development to sales
OrphanPacific was founded by CMIC HOLDINGS, a leading and pioneer contract research organization (CRO) company in Japan, and MEDIPAL HOLDINGS, a leading pharmaceutical products wholesaler with more than 200 facilities across Japan, reaching out to all medical institutions and pharmacies nationwide.
Extensive collaboration with our parent companies which both have robust track records in the medical field allows OrphanPacific to cover the whole spectrum of pharmaceutical activities from development to promotion in Japan.
CMIC Group
Pioneer and Largest Full Service CxO Group in Japan
Corporate overview
-
Company name
CMIC HOLDINGS Co., Ltd.
-
Establishment
March 14, 1985 in Tokyo
-
Representative Directors
Kazuo Nakamura, Ph.D., CEO
-
Capital
¥3.1 Bil. (US$31 mil.)
-
Business Model
Pharmaceutical Value Creator (PVC)
- Maximizing pharmaceutical company’s value
CRO, CDMO, CSO, Healthcare, IPM
Business Activities of the CMIC Group
Contact us
Monday to Friday 9:00 a.m. to 5:30 p.m. on weekdays (Japan time).
